Halyard Health, Inc. (NYSE:HYH)‘s stock had its “buy” rating reaffirmed by equities researchers at Stifel Nicolaus in a report issued on Friday. They presently have a $52.00 price objective on the medical instruments supplier’s stock. Stifel Nicolaus’ price target suggests a potential upside of 9.87% from the company’s current price.

Other research analysts have also issued reports about the stock. Zacks Investment Research upgraded shares of Halyard Health from a “hold” rating to a “buy” rating and set a $44.00 price objective on the stock in a report on Wednesday, July 12th. Deutsche Bank AG increased their price objective on shares of Halyard Health from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Stephens upgraded shares of Halyard Health from an “equal weight” rating to an “overweight” rating in a report on Thursday, August 3rd. TheStreet lowered shares of Halyard Health from a “b-” rating to a “c+” rating in a report on Monday. Finally, BidaskClub lowered shares of Halyard Health from a “buy” rating to a “hold” rating in a report on Saturday, July 8th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $44.00.

Halyard Health (HYH) traded up $2.11 during trading hours on Friday, reaching $47.33. 507,744 shares of the company’s stock were exchanged, compared to its average volume of 456,112. The company has a market cap of $2.20 billion, a PE ratio of 22.49 and a beta of 1.69.

Halyard Health (NYSE:HYH) last announced its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported $0.60 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The business had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a net margin of 3.52% and a return on equity of 8.65%. The company’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $0.48 EPS. analysts forecast that Halyard Health will post 2.08 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright laws. The original version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/03/halyard-healths-hyh-buy-rating-reaffirmed-at-stifel-nicolaus.html.

A number of large investors have recently modified their holdings of the business. BlackRock Inc. grew its position in Halyard Health by 6,362.1% in the first quarter. BlackRock Inc. now owns 5,939,352 shares of the medical instruments supplier’s stock valued at $226,229,000 after acquiring an additional 5,847,442 shares in the last quarter. Vanguard Group Inc. grew its position in Halyard Health by 4.7% in the first quarter. Vanguard Group Inc. now owns 4,350,518 shares of the medical instruments supplier’s stock valued at $165,711,000 after acquiring an additional 196,367 shares in the last quarter. Dimensional Fund Advisors LP grew its position in Halyard Health by 19.3% in the second quarter. Dimensional Fund Advisors LP now owns 3,133,049 shares of the medical instruments supplier’s stock valued at $123,067,000 after acquiring an additional 507,893 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Halyard Health by 242.8% in the second quarter. Goldman Sachs Group Inc. now owns 1,864,646 shares of the medical instruments supplier’s stock valued at $73,244,000 after acquiring an additional 1,320,735 shares in the last quarter. Finally, State Street Corp grew its position in Halyard Health by 7.5% in the second quarter. State Street Corp now owns 1,702,423 shares of the medical instruments supplier’s stock valued at $66,872,000 after acquiring an additional 119,154 shares in the last quarter. 91.03% of the stock is owned by institutional investors.

Halyard Health Company Profile

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

Receive News & Ratings for Halyard Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.